SCHEMBL26523474

SCHEMBL26523474

CN(CC(=O)N1CCCc2ccccc21)Cc1nc2ccccc2c(=O)n1C

nearest known ligand 0.65

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.65
LMNA P02545 6/20 0.65
HTT P42858 4/20 0.65
SMN1; SMN2 Q16637 3/20 0.65
MAPT P10636 4/20 0.55
NPSR1 Q6W5P4 3/20 0.55
TSHR P16473 2/20 0.55
ALOX15 P16050 1/20 0.55
RECQL P46063 1/20 0.48
GAA P10253 1/20 0.47
MAPK1 P28482 1/20 0.47
KDM4E B2RXH2 2/20 0.46
KMT2A Q03164 1/20 0.46
HPGD P15428 1/20 0.46
THRB P10828 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23749976 0.81 PARP1 (0.61) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL8623849 0.74 ALDH1A1 (0.65) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL15203577 0.71 TRPM5 (0.53) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL31504944 0.68 ACKR3 (0.53) ALDH1A1NPSR1TSHRALOX15KDM4E
SCHEMBL29522633 0.68 TSHR (0.67) ALDH1A1SMN1; SMN2MAPTTSHRMAPK1
SCHEMBL711283 0.68 TSHR (0.67) ALDH1A1SMN1; SMN2MAPTTSHRMAPK1
SCHEMBL26521632 0.67 PARP1 (0.54) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL23657663 0.67 HDAC6 (0.56) ALDH1A1LMNAHTTSMN1; SMN2MAPT
SCHEMBL30253474 0.67 SMN1; SMN2 (0.68) ALDH1A1SMN1; SMN2TSHRGAAMAPK1
SCHEMBL29520673 0.67 NOTUM (0.69) ALDH1A1LMNASMN1; SMN2NPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 GAIN THERAPEUTICS SA (CH) 2023-05-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230140216-A1 COMBINATION THERAPY FOR TREATING MPS1 IDUA, MAN2B1, GBA1 ALDH1A1 796/4885LMNA 560/4885HTT 2263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.